MyFinsight
Home
Blog
About
Contact
Net change in cash
and cash...
-$3,131,219
Accrued expenses
$19,444,957
Stock-based compensation
expense
$3,788,275
Accounts receivable, net
of allowances
-$2,970,056
Amortization of in-process
research and development
$1,720,312
Accrued compensation
$507,612
Prepaid expenses
-$178,405
Amortization (accretion) of
operating lease...
$40,659
Proceeds from exercise of
citius oncology...
$818
Net cash used in
operating activities
-$1,300,021
Net cash provided by
financing activities
-$1,231,198
Net cash used in
investing activities
-$600,000
Canceled cashflow
$28,650,276
Canceled cashflow
$818
Net loss
-$28,109,746
Repayment of note payable
$1,000,000
Deferred financing costs
$169,252
Net proceeds from
common stock offerings
-$62,764
License fee payments
$600,000
Accounts payable
-$1,567,609
Deferred income tax
expense
-$231,210
Operating lease liability
-$21,484
Inventory
$20,248
Back
Back
Cash Flow
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)
source: myfinsight.com